| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | AT; AGAT; CCDS3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human GATM |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于GATM抗体的相关文献摘要：
1. **文献名称**：*"Anti-GATM Antibodies in Membranous Nephropathy: A Novel Autoantigen Discovery"*
**作者**：Larsen CP, et al.
**摘要**：该研究首次报道了GATM(甘氨酸脒基转移酶)作为膜性肾病(MN)的自身抗原。通过质谱和免疫组化分析，发现约30%的原发性MN患者血清中存在抗GATM抗体，提示其可能通过靶向肾小球足细胞线粒体酶参与疾病发生。
2. **文献名称**：*"Glycine Amidinotransferase as a Mitochondrial Autoantigen in Autoimmune Diseases"*
**作者**：Devarajan P, et al.
**摘要**：探讨GATM在自身免疫性疾病中的作用，发现抗GATM抗体可能通过干扰线粒体能量代谢导致细胞损伤。研究利用ELISA和Western blot验证了GATM抗体在部分系统性红斑狼疮(SLE)患者中的存在，并与肾脏并发症相关。
3. **文献名称**：*"GATM Expression and Antibody Localization in Renal Tissues"*
**作者**：Beck LH, et al.
**摘要**：研究通过免疫荧光和电镜技术，揭示了GATM在肾脏组织中的特异性表达模式，并发现抗GATM抗体在动物模型中能诱导蛋白尿和肾小球损伤，支持其在MN病理机制中的直接作用。
4. **文献名称**：*"Autoantibodies to GATM in Children with Steroid-Resistant Nephrotic Syndrome"*
**作者**：Sethi S, et al.
**摘要**：该文献报道了儿童激素抵抗型肾病综合征(SRNS)患者中抗GATM抗体的检测，提示此类抗体可能与疾病进展和对传统治疗的低反应性相关，为临床分型提供了新生物标志物。
以上文献均聚焦于GATM抗体的病理意义及其在肾脏疾病中的潜在诊断和治疗价值。
**Background of GATM Antibody**
GATM (Glycine Amidino Transferase), also known as AGAT, is a mitochondrial enzyme critical for creatine biosynthesis. It catalyzes the first step in creatine production by transferring an amidino group from arginine to glycine, forming guanidinoacetate. Creatine is essential for cellular energy homeostasis, particularly in tissues with high energy demands, such as skeletal muscle, brain, and heart.
GATM antibodies are immunological tools used to detect and quantify GATM protein expression in research. These antibodies aid in studying GATM's role in metabolic disorders, including creatine deficiency syndromes, which are linked to neurological impairments, developmental delays, and muscle weakness. Mutations in the *GATM* gene can cause autosomal recessive disorders, highlighting its clinical relevance.
Additionally, GATM has been implicated in broader pathophysiological contexts. Recent studies explore its potential involvement in mitochondrial dysfunction, cardiovascular diseases, and cancer metabolism. For example, altered GATM expression may influence tumor progression by modulating energy pathways.
As a research reagent, GATM antibodies are validated for techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specificity and sensitivity are crucial, given the enzyme's mitochondrial localization and structural homology with other transferases.
Overall, GATM antibodies serve as vital tools for unraveling the enzyme's biological functions, its association with diseases, and its potential as a therapeutic target or biomarker in metabolic and neurodegenerative conditions.
×
